<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499859</url>
  </required_header>
  <id_info>
    <org_study_id>ROSUZET-AMI</org_study_id>
    <nct_id>NCT04499859</nct_id>
  </id_info>
  <brief_title>Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI</brief_title>
  <acronym>ROSUZET-AMI</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Open-label Trial to Compare Low-dose ROSUvastatin Plus eZETimibe Versus High-dose Rosuvastatin in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiyuk Chang, MD,PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate&#xD;
      in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg.&#xD;
&#xD;
      This trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and&#xD;
      ezetimibe among patients with acute myocardial infarction who went through percutaneous&#xD;
      coronary intervention at decreasing major adverse cardiac events compared to the efficacy of&#xD;
      single use of high dose rosuvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) study&#xD;
      showed that even when statin is not used as a treatment the rate of decrease of LDL&#xD;
      cholesterol is correlated to the risk of heart disease. Yet whether concomitant use of&#xD;
      ezetimibe and statin will have similar degree of clinical efficacy as single use of high dose&#xD;
      statin in decreasing LDL cholesterol level needs further examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>24 months</time_frame>
    <description>A composite of cardiovascular death, non-fatal myocardial infarction, ischemic stroke and hospitalization due to unstable angina</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Each clinical outcome from MACE</measure>
    <time_frame>24 months</time_frame>
    <description>Assessment variable including cardiovascular deaths, total deaths, non-fatal myocardial infarction, non-fatal ischemic stroke, hospitalization due to unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization</measure>
    <time_frame>24 months</time_frame>
    <description>any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C reduction</measure>
    <time_frame>3 months</time_frame>
    <description>LDL cholesterol level of 70mg/dL or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Statin associated muscle symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Stain Associated Muscle Symptom questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3548</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Statin Adverse Reaction</condition>
  <condition>HMG-CoA Reductase Inhibitor Toxicity</condition>
  <arm_group>
    <arm_group_label>ezetimibe 10 mg plus rosuvastatin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuzet 5/10 mg , once a day for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin 20 mg only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Any brand drugs of rosuvastatin 20mg, once a day for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuzet 10/5 mg</intervention_name>
    <description>Initial use of 10mg of ezetimibe combined with 5 mg of rosuvastatin</description>
    <arm_group_label>ezetimibe 10 mg plus rosuvastatin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>20mg of Rosuvastatin as a standard treatment for AMI patients</description>
    <arm_group_label>rosuvastatin 20 mg only</arm_group_label>
    <other_name>Crestor 20mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults Aged 19 and up&#xD;
&#xD;
          2. Patients diagnosed with myocardial infarction (both ST segment elevation and non-ST&#xD;
             segment elevation) who were treated with percutaneous coronary intervention&#xD;
             (Myocardial infarction defined as in the 4th Universal Definition of Myocardial&#xD;
             Infarction)&#xD;
&#xD;
          3. For female patients who are of childbearing age, subjects that agreed on taking&#xD;
             mandatory pregnancy test&#xD;
&#xD;
          4. Patients who agreed and signed on the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with life expectancy of a year or less due to malignancy&#xD;
&#xD;
          2. Patients with chronic liver disease&#xD;
&#xD;
          3. Patients with sensitivity to active ingredient of the research drugs (ezetimibe and/or&#xD;
             rosuvastatin) or patients who are prohibited to take ezetimibe and/or rosuvastatin.&#xD;
&#xD;
          4. Pregnant and/or breastfeeding&#xD;
&#xD;
          5. Female patients who are unable to use any means of contraception&#xD;
&#xD;
          6. Patients receiving hemodialysis, peritoneal dialysis patients and/or kidney transplant&#xD;
             patients, due to end stage renal disease&#xD;
&#xD;
          7. Patients who participated in other clinical trial(s) within 3 months from the&#xD;
             screening (except non-interventional observational study)&#xD;
&#xD;
          8. Patients considered inappropriate for the study for any other reason(s) by the&#xD;
             inspector(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyuk Chang, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kiyuk Chang, MD,PhD</last_name>
    <phone>82-10-9175-2076</phone>
    <email>kiyuk@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun Ho Choo, MD</last_name>
    <phone>82-10-8500-4569</phone>
    <email>cmcchu@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bucheon St.Mary Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hee Yeol Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Ki-Dong Yoo, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uijeongbu St.Mary's Hospital</name>
      <address>
        <city>Uijeongbu</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Chan Joon Kim, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daejeon St.Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Man Won Park, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Doo Soo Jeon, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <investigator>
      <last_name>Kiyuk Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeouido St.Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Chul-Soo Park, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Kiyuk Chang, MD,PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

